For more than 25 years, Biomedical Development Corporation has been bringing commercially-viable products to market by linking promising technologies with vital sources of research funding.
Principal Investigator(s)
Gregg Siegel
Funded by
NIH / NIDA
The overall goal of this Fast-Track SBIR project is to evaluate the real-world adoption of KIOS, a patient-centered digital therapeutic / mobile app to assist in the effective self-management of Opioid Use Disorder (OUD). Previous work demonstrated that KIOS could chart the trajectories of patients with OUD by tracking concurrent changes in multiple clinical measures as they interact. KIOS makes it possible to process patient-entered data and provide responsive behavioral advice to patients specific to their condition in real time.
For more than 25 years, Biomedical Development Corporation has been bringing commercially-viable products to market by linking promising technologies with vital sources of research funding.
Principal Investigator(s)
Jennifer Sharpe Potter, Ph.D.
Funded by
NIH / NIDA
Collaborating Institutions
UT Health San Antonio
This Phase II STTR project furthers the development of KIOS, a digital therapeutic for the treatment of opioid use disorder (OUD). The product to be commercialized is an FDA-approved digital therapeutic (DTx) medical device offered adjunctive to medication assisted therapy (MAT). In contrast to other digital products for OUD, only KIOS offers continuously available, individualized, evidence-based behavioral intervention strategies responsive to a patient's current clinical status outside the context of the doctor’s office or treatment facility.
For more than 25 years, Biomedical Development Corporation has been bringing commercially-viable products to market by linking promising technologies with vital sources of research funding.
Principal Investigator(s)
Dr. Charles L. Bowden, M.D.
Susan L. McElroy, M.D.
Rif S. El-Mallakh, M.D.
Funded by
National Institute of Mental Health (NIMH)
The goal of this project is to complete the development of a patient-centered software system and mobile app to assist in managing bipolar disorder. The clinical trial (n=120) is a randomized 52 week, blinded rater comparison of KIOS Bipolar to a popular mood charting program.
